32383-02-1

Basic information

• Product Name: 2,3-Pyridinedicarboxylic acid, dimethyl ester, 1-oxide
• Synonyms: 2,3-Pyridinedicarboxylic acid, dimethyl ester, 1-oxide ;2,3-bis(methoxycarbonyl)pyridine1-oxide;1-Oxy-pyridine-2,3-dicarboxylic acid dimethyl ester;pyridine-2,3-dicarboxylic acid dimethyl ester N-oxide
• CAS NO: 32383-02-1
• Molecular Formula: C₉H₉NO₅
• Molecular Weight: 211.17
• Mol File: 32383-02-1.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2,3-Pyridinedicarboxylic acid, dimethyl ester, 1-oxide(CAS DataBase Reference)
• NIST Chemistry Reference: 2,3-Pyridinedicarboxylic acid, dimethyl ester, 1-oxide(32383-02-1)
• EPA Substance Registry System: 2,3-Pyridinedicarboxylic acid, dimethyl ester, 1-oxide(32383-02-1)

Safety Data

• Hazardous Substances Data: 32383-02-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2,3-Pyridinedicarboxylic acid, dimethyl ester, 1-oxide is used as an intermediate in the synthesis of various pharmaceutical compounds. Its unique structure and reactivity make it a valuable component in the development of new drugs and therapeutic agents.
Used in Agrochemical Industry:
In the agrochemical sector, 2,3-Pyridinedicarboxylic acid, dimethyl ester, 1-oxide is utilized as a precursor for the production of pesticides and other agrochemicals. Its ability to form stable derivatives contributes to the effectiveness and longevity of these products.
Used in Materials Science:
2,3-Pyridinedicarboxylic acid, dimethyl ester, 1-oxide is employed in materials science for the development of advanced materials with specific properties. Its versatility in forming complexes and its stability make it suitable for use in the creation of new materials with tailored characteristics.
Used as an Antioxidant:
2,3-Pyridinedicarboxylic acid, dimethyl ester, 1-oxide has potential use as an antioxidant, protecting materials from oxidative degradation and extending their lifespan. Its ability to scavenge free radicals and prevent oxidation reactions makes it a promising candidate for use in various applications where oxidation resistance is required.
Used as a Stabilizer in Polymers:
In the field of polymer science, 2,3-Pyridinedicarboxylic acid, dimethyl ester, 1-oxide is used as a stabilizer to enhance the stability and performance of polymers. Its incorporation into polymer matrices can improve resistance to environmental factors, such as heat, light, and chemicals, thereby increasing the durability and longevity of the polymers.

Upstream product

• 605-38-9 dimethyl 2,3-pyridinedicarboxylate 
• 89-00-9 Pyridine-2,3-dicarboxylic acid 

Downstream Products

• 32383-03-2 6-chloropyridine-2,3-dicarboxylic acid dimethyl ester 
• 1445596-32-6 methyl 6-cyclopropyl-3-phenylpicolinate 
• 1445596-33-7 methyl 6-cyclopropyl-3-phenylpicolinate 
• 957122-57-5 5,6-bis(hydroxymethyl)pyridine-2-carbonitrile 
• 220001-93-4 (6-chloropyridine-2,3-diyl)dimethanol 
• 220001-94-5 6-chloro-2,3-bis(chloromethyl)pyridine 
• 169745-87-3 2-benzenesulfonyl-5-benzo[1,3]dioxol-5-yl-7-(4-methoxy-phenyl)-5-(2-trimethylsilanyl-ethoxymethoxy)-5H-[1]pyrindine-6-carboxylic acid tert-butyl ester 
• 169745-86-2 5-benzo[1,3]dioxol-5-yl-7-(4-methoxy-phenyl)-2-phenylsulfanyl-5-(2-trimethylsilanyl-ethoxymethoxy)-5H-[1]pyrindine-6-carboxylic acid tert-butyl ester 
• 169745-90-8 5-benzo[1,3]dioxol-5-yl-7-(4-methoxy-phenyl)-2-propylsulfanyl-5-(2-trimethylsilanyl-ethoxymethoxy)-5H-[1]pyrindine-6-carboxylic acid tert-butyl ester 

Relevant articles and documents

TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE

The present disclosure relates to bifunctional compounds, which find utility as modulators of tan protein. In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a VHL or cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds tan protein, such that tan protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of tan. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of tan protein. Diseases or disorders that result from aggregation or accumulation of tan protein are treated or prevented with compounds and compositions of the present disclosure.

From Pyridine- N-oxides to 2-Functionalized Pyridines through Pyridyl Phosphonium Salts: An Umpolung Strategy

The reactions of pyridine-N-oxides with Ph3P under the developed conditions provide an unprecedented route to (pyridine-2-yl)phosphonium salts. Upon activation with DABCO, these salts readily serve as functionalized 2-pyridyl nucleophile equivalents. This umpolung strategy allows for the selective C2 functionalization of the pyridine ring with electrophiles, avoiding the generation and use of unstable organometallic reagents. The protocol operates at ambient temperature and tolerates sensitive functional groups, enabling the synthesis of otherwise challenging compounds.

CGRP ANTAGONIST COMPOUNDS

The disclosures herein relate to novel compounds of Formula (1): and salts thereof, wherein A1, A2, Q, X, R1, R2 and R3 are defined herein, and their use in treating, preventing, ameliorating, control

ANTI-PULMONARY TUBERCULOSIS NITROIMIDAZOLE DERIVATIVE

Disclosed is a substituted nitroimidazole derivative, which is mainly used for treating related diseases caused by mycobacterial infections, such as Mycobacterium tuberculosis, especially being suitable for diseases caused by resistant Mycobacterium tuberculosis.

Boron-Containing Small Molecules as Anti-Inflammatory Agents

Compounds and methods of treating anti-inflammatory conditions are disclosed.

CHEMICAL COMPOUNDS

The invention relates to a novel compound of formula (I) or a stereoisomer, or a racemate or a mixture or a pharmaceutically acceptable salt thereof: wherein: R is phenyl or a 5- or 6-membered heteroaryl ring containing 1 to 3 heteroatoms selected from S, N and O, such rings may be optionally substituted with n groups Q; Q is selected from a group consisting of: C1-C4 alkyl, halogen, halo C1-C4 alkyl, C1-C4 alkoxy, CN, SO2CH3 or a group —O[(CR1R2]pQ1; or Q may be a group Q2; Q1 is phenyl, which may be optionally substituted with n substituents selected from a group consisting of: C1-C4 alkyl, halogen, halo C1-C4 alkyl, C1-C4 alkoxy, CN, or a group Q2; or corresponds to 2,2-difluoro-benzo[d][1,3]dioxol-4-yl; Q2 is a 5- or 6-membered heteroaryl containing at least one nitrogen atom, which may optionally substituted with n substituents selected from a group consisting of: Cl C1-C4 alkyl, halogen, halo C1-C4 alkyl, C1-C4 alkoxy, CN; P is a 6-membered heteroaryl or a 8-1 1 membered bicyclic heteroaryl group, which may be substituted with n substituents selected from a group consisting of: C1-C4 alkyl, halogen, halo C1-C4 alkyl, C1-C4 alkoxy, CN; R1 is hydrogen or C1-C3 alkyl; R2 is hydrogen or C1-C3 alkyl; n is 1, 2 or 3; p is 0, 1 or 2; and with the proviso that when R corresponds to phenyl, P is substituted by at least one CF3; processes for the preparation of those compounds, pharmaceutical compositions containing one or more compounds of formula (I) and their use as dual antagonists of the Orexin 1 and Orexin 2 receptors.

CHEMICAL COMPOUNDS

The invention relates to a novel compound of formula (I) or a stereoisomer, or a racemate or a mixture or a pharmaceutically acceptable salt thereof: wherein: R is phenyl or a 5- or 6-membered heteroaryl ring containing 1 to 3 heteroatoms selected from S, N and O, such rings may be optionally substituted with n groups Q; Q is selected from a group consisting of: C1-C4 alkyl, halogen, halo C1-C4 alkyl, C1-C4 alkoxy, CN, SO2CH3 or a group -O[(CR1R2]pQ1; or Q may be a group Q2; Q1 is phenyl, which may be optionally substituted with n substituents selected from a group consisting of: C1-C4 alkyl, halogen, halo C1-C4 alkyl, C1-C4 alkoxy, CN, or a group Q2; or corresponds to 2,2-difluoro- benzo[d][1,3]dioxol-4-yl; Q2 is a 5- or 6-membered heteroaryl containing at least one nitrogen atom, which may optionally substituted with n substituents selected from a group consisting of: C1 C1-C4 alkyl, halogen, halo C1-C4 alkyl, C1-C4 alkoxy, CN; P is a 6-membered heteroaryl or a 8-1 1 membered bicylic heteroaryl group, which may be substituted with n substituents selected from a group consisting of: C1-C4 alkyl, halogen, halo C1-C4 alkyl, C1-C4 alkoxy, CN; R1 is hydrogen or C1-C3 alkyl; R2 is hydrogen or C1-C3 alkyl; n is 1, 2 or 3; p is 0, 1 or 2; and with the proviso that when R corresponds to phenyl, P is substituted by at least one CF3; processes for the preparation of those compounds, pharmaceutical compositions containing one or more compounds of formula (I) and their use as dual antagonists of the Orexin 1 and Orexin 2 receptors.

MONOCYCLIC CGRP RECEPTOR ANTAGONISTS

The present invention is directed to compounds of the formula (I) : (wherein variables A1, A2, A3, A4, A5, A6, A7, A8, G1, G2, G3, G4, J, Q, Ea, Eb, Ec, R6, R7, RPG and Y are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

Structure-activity relationships of 2-substituted 5,7-Diarylcyclopenteno[1,2-b]pyridine-6-carboxylic acids as a novel class of endothelin receptor antagonists

Synthesis and structure-activity relationships of 2-substituted-5,7-diarylcyclopenteno[1,2-b]pyridine-6-carboxylic acids, a novel class of endothelin receptor antagonists, were described. Derivatization of a lead structure 1 (IC50=2.4 nM, 170-fold selectivity) by incorporating a substituent such as an alkyl, alkoxy, alkylthio, or alkylamino group into the 2-position of the cyclopenteno[1,2-b]pyridine skeleton was achieved via the key intermediate 8. Introduction of an alkyl group led to the identification of potent ETA/ETB mixed receptor antagonists, a butyl (2d: IC50=0.21 nM, 52-fold selectivity) and an isobutyl (2f: IC50=0.32 nM, 26-fold selectivity) analogue. In contrast, installment of a primary amino group resulted in ETA selective antagonists, a propylamino 2p (IC50=0.12 nM, 520-fold selectivity) and an isopropylamino 2q (IC50=0.10 nM, 420-fold selectivity) analogue. These results suggested that a substituent at the 2-position of the 5,7-diarylcyclopenteno[1,2-b]pyridine-6-carboxylic acids played a key role in the binding affinity for both ETA and ETB receptors.